These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 1176815)

  • 1. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition.
    Glover CJ; McIntire LV; Brown CH; Natelson EA
    J Lab Clin Med; 1975 Oct; 86(4):644-56. PubMed ID: 1176815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL; Matsueda GR; Haber E
    Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function.
    Standeven KF; Grant PJ; Carter AM; Scheiner T; Weisel JW; Ariëns RA
    Circulation; 2003 May; 107(18):2326-30. PubMed ID: 12707238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of alpha-polymers and residual alpha-chains in in vitro and in vivo formed fibrin clots.
    Barthels M; Förstermann U; Sosada M; Poliwoda H
    Behring Inst Mitt; 1986 Feb; (79):24-30. PubMed ID: 3718409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
    Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
    Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants.
    Hickerson WL; Nur I; Meidler R
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):19-23. PubMed ID: 21150581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen.
    Shen L; Lorand L
    J Clin Invest; 1983 May; 71(5):1336-41. PubMed ID: 6853717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody against a peptide sequence of fibrinogen gamma chain acts as an inhibitor of factor XIII-mediated crosslinking of human fibrin.
    Taubenfeld SM; Song Y; Sheng D; Ball EL; Matsueda GR
    Thromb Haemost; 1995 Sep; 74(3):923-7. PubMed ID: 8571322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM).
    Theusinger OM; Baulig W; Asmis LM; Seifert B; Spahn DR
    Thromb Haemost; 2010 Aug; 104(2):385-91. PubMed ID: 20431856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions.
    Nielsen VG
    Acta Anaesthesiol Scand; 2005 Sep; 49(8):1163-71. PubMed ID: 16095459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
    Siebenlist KR; Meh DA; Mosesson MW
    Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheology of blood coagulation.
    Kaibara M
    Biorheology; 1996; 33(2):101-17. PubMed ID: 8679959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
    Carroll RC; Lockhart MS; Taylor FB
    J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets.
    Hevessy Z; Haramura G; Boda Z; Udvardy M; Muszbek L
    Thromb Haemost; 1996 Jan; 75(1):161-7. PubMed ID: 8713796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of factor XIII deficiency in acute leukemia with resonance thrombography].
    Anders O; Görss EW; Ernst B; Konrad H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(5):670-9. PubMed ID: 2448208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
    Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
    Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fibrinogen-, factor VIII- and XIII-mediated clot propagation in gelatin haemodilution.
    Schramko AA; Kuitunen AH; Suojaranta-Ylinen RT; Niemi TT
    Acta Anaesthesiol Scand; 2009 Jul; 53(6):731-5. PubMed ID: 19239406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
    Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)].
    Klingemann HG; Brunswig D; Liehr H
    Z Gastroenterol; 1978 Sep; 16(9):564-73. PubMed ID: 706517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological studies of coagulation factor XIII.
    Israels ED; Paraskevas F; Israels LG
    J Clin Invest; 1973 Oct; 52(10):2398-403. PubMed ID: 4199604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.